Search results
Jun 27, 2024 · NORTH CHICAGO, Ill., June 27, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) announced today the acquisition of Celsius Therapeutics, Inc. (“Celsius”), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease.
Jun 28, 2024 · June 28, 2024. The strategic move expands AbbVie’s footprint in the treatment of inflammatory diseases. Credit: Kmpzzz / Shutterstock. AbbVie has acquired biotechnology company Celsius Therapeutics in a deal valued at $250m in cash. Celsius focuses on developing new treatments for inflammatory diseases.
Jun 27, 2024 · Celsius' lead investigational asset is CEL383, a potential first-in-class anti-TREM1 antibody that has completed a Phase 1 clinical study for the treatment of IBD. TREM1 has been identified as a key disease driver gene in IBD, where it is expressed on inflammatory monocytes and neutrophils.
Jun 13, 2024 · NORTH CHICAGO, Ill. and BEIJING, June 13, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) and FutureGen Biopharmaceutical ( Beijing) Co., Ltd. today announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of IBD currently in preclinical development.
4 days ago · AbbVie is not owned by hedge funds. The company's largest shareholder is The Vanguard Group, Inc., with ownership of 9.6%. BlackRock, Inc. is the second largest shareholder owning 8.1% of common ...
Jun 19, 2024 · “Today’s approval of SKYRIZI for ulcerative colitis expands our IBD portfolio and demonstrates our commitment to helping address ongoing needs of patients,” said Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, AbbVie. “We will continue to invest in transforming the treatment landscape and the ...
Jun 17, 2024 · US-based firm AbbVie and FutureGen Biopharmaceutical (Beijing) have announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of inflammatory bowel disease (IBD) currently in preclinical development.
